Home Analyst Ratings Barclays lowers Arcturus Therapeutics Holdings Inc (ARCT) rating to Equal Weight and...

Barclays lowers Arcturus Therapeutics Holdings Inc (ARCT) rating to Equal Weight and sets price target at $46

Barclays took its Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)‎ rating to the equivalent of Equal ‎Weight from Overweight, and the price target to $46,‎ ‎in a research note ‎dated December 29, 2020. ‎Other ‎analysts also revised their coverage, with ROTH Capital’s analysts downgrading the shares from ‎‎”a Buy” ‎rating to “a Sell” rating in a research note to investors issued in late December. Meanwhile, B. ‎Riley ‎Securities had maintained its rating on ARCT to the earlier “Buy” rating, in a research note ‎produced for ‎clients December 08, 2020. In addition, there was no change from B. Riley Securities on ‎December 07, ‎‎2020. The rater maintained ARCT to “a Buy” but assigned new target price of $111.

Get the hottest stocks to trade every day before the market ‎opens 100% ‎free. Click here now. 

Is Arcturus Therapeutics Holdings Inc. [NASDAQ:ARCT] a Good Buy Right Now?

It should ‎be ‎noted that ARCT technical indicators for short, intermediate as well as long term progress have ‎placed ‎an overall average of 88% as Buy. The average signal changed from 100% Buy in the last week ‎and ‎compares with 88% Buy in the past month. Data from Arcturus Therapeutics Holdings Inc.’s ‎Trend ‎Spotter indicated that the signals were Weakest. The stock current average is 1.65 million shares ‎in the ‎past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the ‎average ‎trading volume was 1.16 million shares while the medium term average advocated for 100% ‎Buy. The ‎average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.92 ‎million ‎shares.‎‎


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


ARCT Price Performance

On Wall Street, Arcturus Therapeutics Holdings ‎Inc. ‎‎[NASDAQ:ARCT] finished Monday’s session down -5.82% at $92.42. The stock went up to $103.00 ‎at ‎the same session while its lowest single day price was $92.125. In the last five days, it saw a fall ‎of ‎about -6.92%, Arcturus Therapeutics Holdings Inc. shares gained by almost 750.23% since the ‎beginning ‎of the year. However, the share price has dropped to as low as -28.75% below its one year ‎high. On ‎‎12/07/20, the company shares recorded $129.71, the highest single-day price it has got to in ‎the last 52-‎weeks and a 52-week low was seen on 03/13/20, the same year at $8.51. The company’s ‎shares have ‎inclined by 706.46% in the past year. The 50-day SMA achieved is $73.07 while the 200-day ‎SMA is ‎‎$48.59. Volume gained to 1.82 million from 1.56 million in the previous session.‎‎

ARCT Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing ‎is ‎perceived around 88.70 level, and in case of violation of this particular level, it will cause more drop ‎to ‎‎84.97 level. On the upper level, 106.72 is still the key resistance. The stock may increase to ‎the ‎subsequent resistance at 99.57. The Relative Strength Index (RSI) pinned on the 14-day chart is ‎‎50.23, ‎implying a neutral technical stance while the MACD stands at -5.87, meaning price will decrease ‎in the ‎next trading period. Percent R indicator moved to 89.97%, implying bearish price ‎movement. ‎Stochastic %K at 18.42% suggest selling the stock.‎‎

What is the short interest in Arcturus Therapeutics Holdings Inc.?

Short interest in ‎the ‎Arcturus Therapeutics Holdings Inc. stock has surged, increasing by 0.99 million shares to total ‎‎3.7 ‎million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 4.69 million, ‎data ‎from Yahoo Finance shows. The decrease of -26.76% suggests the stock saw some decreased ‎bullish ‎sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account ‎for just ‎‎19.58% of the overall float for the stock.‎‎

Arcturus Therapeutics Holdings Inc.’s Biggest Shareholders: Who Owns Arcturus ‎Therapeutics ‎Holdings Inc. [ARCT]?

Filings by ARK Investment Management LLC showed that the ‎firm now ‎holds a total of 2,495,842 shares or roughly 10.19% of the outstanding ARCT shares. This ‎means their ‎shares have increased by 577,007 from the 2,495,842 the investor reportedly held in its ‎prior 13-F filing. ‎With the conclusion of the purchase, HealthCor Management LP updated stake is ‎worth $146,306,916. ‎Details in the latest 13F filings reveal that SSgA Funds Management, Inc. acquired ‎their 504.70% stake ‎valued at $143,168,907 while Federated Global Investment Manag added theirs at ‎‎$125,252,400. During ‎the last quarter, SSgA Funds Management, Inc. raised 1,302,232 of its shares in ‎Arcturus Therapeutics ‎Holdings Inc. while Federated Global Investment Manag bought 750,000 shares. ‎The BlackRock Fund ‎Advisors’s holdings currently number 1,032,203 shares at $95396201.26. According ‎to the firm’s last 13F ‎report, The Vanguard Group, Inc. shares in the company at filing stood at 984,328 ‎shares, roughly ‎‎$90,321,937.‎‎

ARCT Earnings Forecast For The Current Quarter

Arcturus Therapeutics Holdings Inc. ‎‎[ARCT] ‎is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus ‎estimates ‎give the company expected revenues of $2.36M and an earnings per share of -$0.89 for Dec ‎‎2020. ‎Looking further ahead, the company is expected to report revenue of $10.96M at an EPS of -‎‎$0.58 for ‎Mar 2021. The estimates represent downside of 1,821.10% and 106.50% in the company’s ‎revenue and ‎earnings per share, respectively, on a year-on-year basis.‎‎

Get the hottest stocks to trade every day before the market ‎opens 100% ‎free. Click here now. 

ARCT Earnings Estimates For The ‎Current ‎Year

For the financial year, Arcturus Therapeutics Holdings Inc. [NASDAQ:ARCT] is ‎expected to ‎bring in revenue of $9.76M. The returns are nearly $-11.03 million lower than the ‎company’s actual ‎revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it ‎at -3.1, lower ‎than that of FY19 by -$0.95. Estimates put this year’s earnings growth at -44.20%, 106.50% ‎for the next. As for sales, forecasts are for a decrease of -53.10% ‎in the current fiscal year and a further ‎‎1,821.10% over the following year.‎

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Why Is BTZI Stock Increasing Today?

The stock price of BOTS, Inc. (OTCPink: BTZI) has been rising more than 7% today and was buoying at $0.1266 at the last check....

Why Has The KBSF Stock Price Gained 10% In Last Session?

As of Friday's normal trading session, the price of KBS Fashion Group Limited (NASDAQ: KBSF) rose $0.26 or 9.96% to conclude at $2.87. KBS...

Why Royal Bank of Canada (RY) stock plummeted in after-hours on Friday?

Royal Bank of Canada (RY) stock lost 64.36% in the extended hour trading session on Friday, April 16, 2021. The RY stock gained merely...

Why Did The CMCL Stock Rise By 8% In Last Trading?

Caledonia Mining Corporation Plc (NYSE: CMCL) gained 8.91% during the trading session on Thursday. The share price reached a low of $13.70 and a...

Why Progyny Inc (PGNY) stock gained on Thursday, April 15?

Progyny Inc (PGNY) stock gained 7.31% in the after-hours session on Thursday, April 15, 2021, after it gained 0.94% in the early session.  PGNY...

Is This Why The APLD Stock Skyrocketed Last Trading?

Applied Science Products, Inc. (OTCPK: APLD) closed at $0.635 and experienced a 215.92% increase on Friday. A total of 2.07M shares of Applied Science...

The CRSS Stock Increased 82% In The Last Session Due To What?

Stock of Crossroads Systems, Inc. (OTCQX: CRSS) gained 81.82% or $18.00 in Friday's trading session, closing the day at $40.00 a share. Crossroads Systems...

How Did The ZVO Stock Appreciate 9% In The Last Trading Session?

Zovio Inc (NASDAQ: ZVO) normally sees about 413.34K shares traded on a regular business day but on a Friday it saw a bit higher...

Related News

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

Raymond James upgrades Atlantic Capital [ACBI] to Outperform

Raymond James took its Atlantic Capital rating to the equivalent of Outperform from Market Perform, in a research note dated 2021-01-25. Other analysts...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.